PCD test provides definitive diagnosis of a rare disease - Insights
Joseph Maleszewski, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD). Mayo Clinic's expertise and technology have earned the laboratory's...
Inflammatory Bowel Disease: IBDP2 - Insights
In this test specific episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
Urologic panels provide focused cancer testing: Sounak Gupta, M.B.B.S., Ph.D. - Insights
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS...
Colorectal panel provides detailed cancer information - Insights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.
Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the...
Direct Ethanol Biomarker Testing: PETH - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for...
Christmas Specimen Shipping Guidelines and Schedule - Insights
Due to the Christmas holiday (recognized on Wednesday, Dec. 25), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure specimen stability and prevent delays, follow the guidelines outlined below for...
New tests launched in February - Insights
In February 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
New tests launched in May - Insights
In May 2022, Mayo Clinic Laboratories announced multiple new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Extended Spectrum Beta Lactamase Testing - Insights
Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool...